EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, announced today that its U.S. marketing partner, Perrigo Company, has received approval from the U.S. Food and Drug Administration (FDA) to market generic simvastatin 5 mg, 10 mg, 20 mg, 40 mg and 80 mg tablets in the U.S. The FDA has determined that these formulations, which will be manufactured at Bentley’s facilities in Spain, are bioequivalent and have the same therapeutic effect as that of the reference drug, Zocor® (Merck & Co.), whose patent expired on June 23, 2006 and 180-day exclusivity period expired on December 19, 2006.
